Cargando…

Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells

SIMPLE SUMMARY: Glucocorticoid therapy resistance in B-cell malignancies is often associated with constitutive activation of tyrosine kinases. Novel anticancer drugs targeting hyperactivated tyrosine kinases, such as Bruton’s tyrosine kinase (BTK), have, therefore, gained much interest over the past...

Descripción completa

Detalles Bibliográficos
Autores principales:	Logie, Emilie, Chirumamilla, Chandra S., Perez-Novo, Claudina, Shaw, Priyanka, Declerck, Ken, Palagani, Ajay, Rangarajan, Savithri, Cuypers, Bart, De Neuter, Nicolas, Mobashar Hussain Urf Turabe, Fazil, Kumar Verma, Navin, Bogaerts, Annemie, Laukens, Kris, Offner, Fritz, Van Vlierberghe, Pieter, Van Ostade, Xaveer, Berghe, Wim Vanden
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037275/ https://www.ncbi.nlm.nih.gov/pubmed/33807411 http://dx.doi.org/10.3390/cancers13071618

Ejemplares similares

The steroidal lactone withaferin A impedes T-cell motility by inhibiting the kinase ZAP70 and subsequent kinome signaling
por: Fazil, Mobashar Hussain Urf Turabe, et al.
Publicado: (2021)

Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19
por: Verma, Navin Kumar, et al.
Publicado: (2020)

Tackling Chronic Inflammation with Withanolide Phytochemicals—A Withaferin A Perspective
por: Logie, Emilie, et al.
Publicado: (2020)

GSK3β Interacts With CRMP2 and Notch1 and Controls T-Cell Motility
por: Fazil, Mobashar Hussain Urf Turabe, et al.
Publicado: (2021)

Selective Glucocorticoid Receptor Properties of GSK866 Analogs with Cysteine Reactive Warheads
por: Chirumamilla, Chandra S., et al.
Publicado: (2017)

A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics
por: Van Damme, Ellen, et al.
Publicado: (2010)

Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols
por: Suttana, Wipob, et al.
Publicado: (2010)

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
por: Wang, Qi, et al.
Publicado: (2015)

Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells
por: Logie, Emilie, et al.
Publicado: (2021)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A
por: vel Szic, Katarzyna Szarc, et al.
Publicado: (2017)

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
por: Bam, R, et al.
Publicado: (2014)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
por: Ringheim, Garth E., et al.
Publicado: (2021)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

GapmeR cellular internalization by macropinocytosis induces sequence-specific gene silencing in human primary T-cells
por: Fazil, Mobashar Hussain Urf Turabe, et al.
Publicado: (2016)

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
por: Ghoshdastidar, Krishnarup, et al.
Publicado: (2020)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma
por: Yeh, Chi-Tai, et al.
Publicado: (2021)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
por: Xiao, Zhou-Peng, et al.
Publicado: (2023)

Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages
por: Strijbis, Karin, et al.
Publicado: (2013)

Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype
por: Sala, Luca, et al.
Publicado: (2019)

Bruton tyrosine kinase (BTK) may be a potential therapeutic target for interstitial cystitis/bladder pain syndrome
por: Wang, Guang, et al.
Publicado: (2022)

A novel Bruton’s tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia
por: Zheng, Bixia, et al.
Publicado: (2014)

Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes
por: Wei, Li, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2020)

IPA Analysis of Cervicovaginal Fluid from Precancerous Women Points to the Presence of Biomarkers for the Precancerous State of Cervical Carcinoma
por: Van Ostade, Xaveer, et al.
Publicado: (2014)

Ectopic MicroRNA-150-5p Transcription Sensitizes Glucocorticoid Therapy Response in MM1S Multiple Myeloma Cells but Fails to Overcome Hormone Therapy Resistance in MM1R Cells
por: Palagani, Ajay, et al.
Publicado: (2014)

Experimental Evidence on the Nature of the Antigen in the Direct Agglutination Test for Visceral Leishmaniasis
por: Kühne, Vera, et al.
Publicado: (2020)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

Candidate biomarkers in the cervical vaginal fluid for the (self-)diagnosis of cervical precancer
por: Van Ostade, Xaveer, et al.
Publicado: (2017)

PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
por: Linton, Kim, et al.
Publicado: (2023)

Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines
por: Kozaki, Ryohei, et al.
Publicado: (2018)

ANKRD54 preferentially selects Bruton’s Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library
por: Gustafsson, Manuela O., et al.
Publicado: (2017)

High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma
por: Yue, Chenglong, et al.
Publicado: (2017)

HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review
por: Derbie, Awoke, et al.
Publicado: (2020)

Pharmacological Levels of Withaferin A (Withania somnifera) Trigger Clinically Relevant Anticancer Effects Specific to Triple Negative Breast Cancer Cells
por: Szarc vel Szic, Katarzyna, et al.
Publicado: (2014)

Antimicrobial Activity and Cell Selectivity of Synthetic and Biosynthetic Cationic Polymers
por: Venkatesh, Mayandi, et al.
Publicado: (2017)

Ferroptosis Induction in Multiple Myeloma Cells Triggers DNA Methylation and Histone Modification Changes Associated with Cellular Senescence
por: Logie, Emilie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hk4qn2dqgqe5cldimokehuijrb